CLARITY: Application of speCtraL Computed tomogrAphy to impRove specIficity of Cardiac compuTed tomographY

Sponsor
UMC Utrecht (Other)
Overall Status
Unknown status
CT.gov ID
NCT03139006
Collaborator
(none)
75
1
53.1
1.4

Study Details

Study Description

Brief Summary

Cardiovascular disease remains the leading cause of morbidity and mortality worldwide. Coronary computed tomography angiography (CCTA) and, if indicated, invasively measured fractional flow reserve (FFR) is currently used for ruling out significant coronary artery disease. FFRCT is a novel non-invasive technique in which FFR is derived from CT images, however this method is currently, just like CCTA, lacking specificity. Spectral Detector CT (SDCT) is a novel technique whereby a spectrum of monoenergetic images at different kiloelectron Volt (keV) values (40 to 200 keV) can be reconstructed. By using these monoenergetic images, a decrease in blooming and beam-hardening artifacts could be achieved. In addition, SDCT offers the opportunity to assess myocardial iodine distribution and quantification. When combining these factors, we hypothesize more accurate information will be available about the coronary anatomy, degree of stenosis and FFRCT and thereby contribute to a more accurate way for the detection of hemodynamic significant stenosis. Therefore, the aim of this study is to assess the accuracy of SDCT as a non-invasive way for the detection of hemodynamically significant coronary artery stenosis.

Objective: The overall objective of this project is to assess the accuracy of SDCT for the detection of flow limiting stenosis in the coronary arteries using invasive FFR as the standard of reference. Whereby different sub-aims (e.g. improvement of FFRCT) are made to answer the overall objective. The secondary objective is to determine the decrease of calcium blooming of calcifications and beam-hardening artifacts and the improvement of myocardial blood volume quantification on SDCT in comparison with conventional CT.

Condition or Disease Intervention/Treatment Phase
  • Device: Dual-layer spectral detector CT

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
75 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Diagnostic Accuracy of Spectral Computed Tomography for Detection of Flow Limiting Coronary Stenosis Using Fractional Flow Reserve as the Standard of Reference
Actual Study Start Date :
Mar 29, 2017
Anticipated Primary Completion Date :
Mar 29, 2021
Anticipated Study Completion Date :
Sep 1, 2021

Outcome Measures

Primary Outcome Measures

  1. Flow limiting stenosis in the coronary arteries defined by invasive fractional flow reserve (FFR) [within 30 days]

    An invasive FFR <0.8 indicates a flow limiting stenosis

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ≥18 years old;

  • Suspected or known stable angina with pre-test likelihood of 50-85% for obstructive coronary disease, using the method recommended by the European Society of Cardiology 2013 Guidelines on the management of stable coronary artery disease (Eur Heart J 2013);

  • Referred for invasive testing with fractional flow reserve;

  • Willing and able to give informed consent. The consent procedures, as set by the Institutional Review Board (IRB) will be followed.

Exclusion Criteria:
  • Subjects with suspected or known stable angina with pre-test likelihood of 0-50% using the method recommended by the European Society of Cardiology 2013 Guidelines on the management of stable coronary artery disease (Eur Heart J 2013 [24]);

  • Subjects who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent or tolerate the coronary CTA examination;

  • Subjects with (severe) renal insufficiency, indicated as glomerular filtration rate (GFR) <60 ml/min;

  • Subjects with unknown GFR or obtained >3 months before the planned scan;

  • Contraindication or allergy to intravenous contrast agent(s);

  • Subjects who participate in an other study with radiation which is estimated to be in risk category III (ICRP 62);

  • Subjects who are pregnant;

  • Subjects with contraindications to cardiac CT and/or S&S protocol, intravenous contrast, intravenous adenosine, betablockers or nitroglycerine.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Medical Center UtrechtU Utrecht Netherlands 3508GA

Sponsors and Collaborators

  • UMC Utrecht

Investigators

  • Principal Investigator: Tim Leiner, MD, PhD, UMC Utrecht

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Tim Leiner, Prof. Dr., UMC Utrecht
ClinicalTrials.gov Identifier:
NCT03139006
Other Study ID Numbers:
  • NL55917.041.16
First Posted:
May 3, 2017
Last Update Posted:
Oct 17, 2018
Last Verified:
Oct 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 17, 2018